SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )1
Barrier Therapeutics, Inc.
------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 par value
------------------------------------------------------------------------------
(Title of Class of Securities)
06850R 10 8
------------------------------------------------------------------------------
(CUSIP Number)
April 28, 2004
-----------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
--------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act.
CUSIP No. 06850R 10 8 Page 2 of 8 Pages
--------------------------------
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson
22-1024240
--------------------------------
2. CHECK THE APPROPRIATE BOX IF (a) [ ]
A MEMBER OF A GROUP (b) [ ]
--------------------------------
3. SEC USE ONLY
--------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
--------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 6. SHARED VOTING POWER
REPORTING
PERSON WITH
4,448,076 shares of Common Stock
------------------------------------------
7. SOLE DISPOSITIVE POWER
-0-
------------------------------------------
8. SHARED DISPOSITIVE POWER
4,448,076 shares of Common Stock
--------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,448,076 shares of Common Stock
--------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
--------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
20.36%
--------------------------------
12. TYPE OF REPORTING PERSON
CO
--------------------------------
CUSIP No. 06850R 10 8 Page 3 of 8 Pages
--------------------------------
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson Consumer Companies, Inc.
--------------------------------
2. CHECK THE APPROPRIATE BOX IF (a) [ ]
A MEMBER OF A GROUP (b) [ ]
--------------------------------
3. SEC USE ONLY
--------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 6. SHARED VOTING POWER
REPORTING
PERSON 1,016,666 shares of Common Stock
WITH
-------------------------------------------
7. SOLE DISPOSITIVE POWER
-0-
-------------------------------------------
8. SHARED DISPOSITIVE POWER
1,016,666 shares of Common Stock
--------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,016,666 shares of Common Stock
--------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
--------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.7%
--------------------------------
12. TYPE OF REPORTING PERSON
CO
--------------------------------
CUSIP No. 06850R 10 8 Page 4 of 8 Pages
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson Development Corporation
22-2007137
--------------------------------
2. CHECK THE APPROPRIATE BOX IF (a) [ ]
A MEMBER OF A GROUP (b) [ ]
--------------------------------
3. SEC USE ONLY
--------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
--------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 6. SHARED VOTING POWER
REPORTING
PERSON 281,410 shares of Common Stock
WITH
------------------------------------------
7. SOLE DISPOSITIVE POWER
-0-
------------------------------------------
8. SHARED DISPOSITIVE POWER
281,410 shares of Common Stock
--------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
281,410 shares of Common Stock
--------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
--------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.3%
--------------------------------
12. TYPE OF REPORTING PERSON
CO
--------------------------------
CUSIP No. 06850R 10 8 Page 5 of 8 Pages
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Janssen Pharmaceutica Products, L.P.
--------------------------------
2. CHECK THE APPROPRIATE BOX IF (a) [ ]
A MEMBER OF A GROUP (b) [ ]
--------------------------------
3. SEC USE ONLY
--------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------
NUMBER OF 5. SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 6. SHARED VOTING POWER
REPORTING
PERSON 3,150,000 shares of Common Stock
WITH
------------------------------------------
7. SOLE DISPOSITIVE POWER
-0-
------------------------------------------
8. SHARED DISPOSITIVE POWER
3,150,000 shares of Common Stock
--------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,150,000 shares of Common Stock
--------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
--------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.4%
--------------------------------
12. TYPE OF REPORTING PERSON
PN
--------------------------------
CUSIP No. 06850R 10 8 Page 6 of 8 Pages
Schedule 13G
------------
ITEM 1(a) - NAME OF ISSUER:
Barrier Therapeutics, Inc.
ITEM 1(b) - ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
600 College Road East
Suite 3200
Princeton, NJ 08540
ITEM 2(a) - NAME OF PERSON FILING:
This statement is being filed by Johnson & Johnson, a New Jersey
corporation ("J&J"), Johnson & Johnson Development Corporation, a New Jersey
corporation ("JJDC"), Janssen Pharmaceutica Products, L.P., a Delaware limited
partnership ("JPP"), and Johnson & Johnson Consumer Companies, Inc., a Delaware
corporation ("JJCC"). JJDC, JPP and JJCC are wholly-owned subsidiaries of J&J.
The securities reported herein as being held by J&J, JJDC, JPP and JJCC are
directly beneficially owned by JJDC, JPP and JJCC. J&J may be deemed to
indirectly beneficially own the securities that are directly beneficially owned
by JJDC, JPP and JJCC.
ITEM 2(b) - ADDRESS OF PRINCIPAL BUSINESS OFFICE:
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
ITEM 2(c) - CITIZENSHIP:
J&J: New Jersey
JJDC: New Jersey
JPP: Delaware
JJCC: Delaware
ITEM 2(d) - TITLE OF CLASS OF SECURITIES:
Common Stock, $.0001 par value per share ("Common Stock")
ITEM 2(e) - CUSIP NUMBER:
06850R 10 8
ITEM 3 - STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR
13D-2(B) OR (C):
Not applicable.
ITEM 4 - OWNERSHIP:
(a) Amount Beneficially Owned:
J&J: 4,448,076 shares of Common Stock
JJDC: 281,410 shares of Common Stock
JPP: 3,150,000 shares of Common Stock
JJCC: 1,016,666 shares of Common Stock
CUSIP No. 06850R 10 8 Page 7 of 8 Pages
(b) Percent of Class:
J&J: 20.36%
JJDC: 1.3%
JPP: 14.4%
JJCC: 4.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: -0-
(ii) shared power to vote or to direct the vote:
J&J: 4,448,076 shares of Common Stock
JJDC: 281,410 shares of Common Stock
JPP: 3,150,000 shares of Common Stock
JJCC: 1,016,666 shares of Common Stock
(iii) sole power to dispose or to direct the disposition of:
-0-
(iv) shared power to dispose or to direct the disposition of:
J&J: 4,448,076 shares of Common Stock
JJDC: 281,410 shares of Common Stock
JPP: 3,150,000 shares of Common Stock
JJCC: 1,016,666 shares of Common Stock
ITEM 5 - OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
Not applicable.
ITEM 6 - OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
Not applicable.
ITEM 7 - IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
Not applicable.
ITEM 8 - IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
Not applicable.
ITEM 9 - NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
ITEM 10 - CERTIFICATION:
Not applicable.
CUSIP No. 06850R 10 8 Page 8 of 8 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
JOHNSON & JOHNSON
By /s/ MICHAEL H. ULLMANN
----------------------
Name: Michael H. Ullmann
Title: Secretary
JOHNSON & JOHNSON DEVELOPMENT
CORPORATION
By /s/ MANISH YADAV
----------------
Name: Manish Yadav
Title: Secretary
JANSSEN PHARMACEUTICA, L.P.
By Janssen Pharmaceutica, Inc.,
General Partner
By /s/ MIKE C. CHESTER
--------------------
Name: Mike C. Chester
Title: Secretary
JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
By /s/ DONNA M. MALIN
------------------
Name: Donna M. Malin
Title: Secretary
Dated: February 1, 2005